SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol 2008; 14: 331-337.
  • 2
    Silveira MG, Lindor KD. Primary sclerosing cholangitis. Can J Gastroenterol 2008; 22: 689-698.
  • 3
    Gordon FD. Primary sclerosing cholangitis. Surg Clin North Am 2008; 88: 1385-1407.
  • 4
    Talwalkar JA, Lindor KD. Primary sclerosing cholangitis. Inflamm Bowel Dis 2005; 11: 62-72.
  • 5
    Lee Y-M, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332: 924-933.
  • 6
    Loftus EV Jr, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-96.
  • 7
    Escorsell A, Pares A, Rodes J, Solis-Herruzo JA, Miras M, De la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. J Hepatol 1994; 21: 787-791.
  • 8
    Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol 2008; 48: 939-944.
  • 9
    Lindkvist B, Benito de Valle M, Gullberg B, Björnsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. HEPATOLOGY 2010; 52: 571-577.
  • 10
    LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, et al. Primary sclerosing cholangitis: summary of a workshop. HEPATOLOGY 2006; 44: 746-764.
  • 11
    Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 2007; 102: 1042-1049.
    Direct Link:
  • 12
    Kingham JGC, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004; 126: 1929-1930.
  • 13
    Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125: 1364-1369.
  • 14
    Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998; 33: 99-103.
  • 15
    Berdal JE, Ebbesen J, Rydning A. Incidence and prevalence of autoimmune liver diseases [in Norwegian]. Tidsskr Nor Laegeforen 1998; 118: 4517-4519.
  • 16
    Kochhar R, Goenka MK, Das K, Nagi B, Bhasin DK, Chawla YK, et al. Primary sclerosing cholangitis: an experience from India. J Gastroenterol Hepatol 1996; 11: 429-433.
  • 17
    Nikolaidis NL, Giouleme OI, Tziomalos KA, Patsiaoura K, Kazantzidou E, Voutsas AD, et al. Small-duct primary sclerosing cholangitis. A single-center seven-year experience. Dig Dis Sci 2005; 50: 324-326.
  • 18
    Miloh T, Arnon R, Shneider B, Suchy F, Kerkar N. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol 2009; 7: 239-245.
  • 19
    Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska natives. Am J Gastroenterol 2002; 97: 2402-2407.
    Direct Link:
  • 20
    Habior A, Walewska-Zielecka B, Butruk, E. Variant forms of autoimmune liver diseases. Gastroenterol Pol 2003; 10: 359-364.
  • 21
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283: 2008-2012.
  • 22
    National Cancer Institute. Surveillance research. http://surveillance.can cer.gov/joinpoint. Accessed January 2011.
  • 23
    Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-1517.
  • 24
    Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 2006; 367: 1271-1284.
  • 25
    Lowe AM, Roy PO, B-Poulin M, Michel P, Bitton A, St-Onge L, et al. Epidemiology of Crohn's disease in Quebec, Canada. Inflamm Bowel Dis 2009; 15: 429-435.
  • 26
    Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006; 101: 1559-1568.
    Direct Link:
  • 27
    Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between North and South? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39: 690-697.
  • 28
    Björnsson E, Boberg KM, Cullen S, Fleming K, Clausen OP, Fausa O, et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002; 51: 731-735.
  • 29
    Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101: 1274-1282.
  • 30
    Fonager K, Sorensen HT, Olsen J. Change in incidence of Crohn's disease and ulcerative colitis in Denmark. A study based on the National Registry of Patients, 1981-1992. Int J Epidemiol 1997; 26: 1003-1008.
  • 31
    Trallori G, d'Albasio G, Palli D, Bardazzi G, Cipriani F, Frittelli G, et al. Epidemiology of inflammatory bowel disease over a 10-year period in Florence (1978-1987). Ital J Gastroenterol 1991; 23: 559-563.
  • 32
    Kitahora T, Utsunomiya T, Yokota A. Epidemiological study of ulcerative colitis in Japan: incidence and familial occurrence. J Gastroenterol 1995; 30( Suppl 8): 5-8.
  • 33
    Hekimoglu K, Ustundag Y, Dusak A, Erdem Z, Karademir B, Aydemir S, et al. MRCP vs ERCP in the evaluation of biliary pathologies: review of current literature. J Dig Dis 2008; 9: 162-169.
  • 34
    Schrumpf E, Boberg KM. Epidemiology of primary sclerosing cholangitis. Baillieres Best Pract Res Clin Gastroenterol 2001; 15: 553-562.
  • 35
    Textor HJ, Flacke S, Pauleit D, Keller E, Neubrand M, Terjung B, et al. Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. Endoscopy 2002; 34: 984-990.
  • 36
    Fulcher AS, Turner MA, Franklin KJ, Shiffman ML, Sterling RK, Luketic VA, et al. Primary sclerosing cholangitis: evaluation with MR cholangiography—a case-control study. Radiology 2000; 215: 71-80.
  • 37
    Kaltenthaler E, Walters S, Chilcott J, Blakeborough A, Vergel Y, Thomas S. MRCP compared to diagnostic ERCP for diagnosis when biliary obstruction is suspected: a systematic review. BMC Med Imaging 2006; 6: 9.
  • 38
    Ardizzone S, Gabriele Bianchi P. Biologic therapy for inflammatory bowel disease. Drugs 2005; 65: 2253-2286.
  • 39
    Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122: 1592-1608.
  • 40
    Hanauer S. Evolutionary biologic therapy for inflammatory bowel disease. Curr Gastroenterol Rep 1999; 1: 467-469.
  • 41
    Ierardi E, Della Valle N, Cosimo Nacchiero M, De Francesco V, Stoppino G, Panella C. Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin Drug Investig 2006; 26: 673-676.
  • 42
    Khokhar OS, Lewis JH. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis 2010; 28: 508-518.
  • 43
    World Bank. World development indicators database. http://data.world bank.org/data-catalog. Accessed January 2011.